Future high-quality prospective studies and randomized controlled trials are needed to further delineate the specific relationships between AID subtypes, autoantibody profiles, and delirium, and to evaluate the potential of individualized immunomodulatory strategies in improving neuropsychiatric outcomes. This evidence concerns the gene AICDA and delirium.